BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal CancerZacks Investment Research • 12/24/24
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic ArthritisBusiness Wire • 12/23/24
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal CancerBusiness Wire • 12/23/24
Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 ProspectsSeeking Alpha • 12/20/24
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring IncomeThe Motley Fool • 12/19/24
Imbed Biosciences Appoints Bristol Myers Squibb Veteran Terry Bromley as Chief Executive OfficerBusiness Wire • 12/19/24
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025Business Wire • 12/19/24
These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?The Motley Fool • 12/19/24
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody programPRNewsWire • 12/19/24
Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet HealthcarePRNewsWire • 12/19/24
Bristol Myers Stock Surges 36.5% in Six Months: Time to Buy or Sell?Zacks Investment Research • 12/10/24
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding PipelineBusiness Wire • 12/09/24
Bristol-Myers Squibb Company (BMY) Citi's 2024 Global Healthcare Conference (Transcript)Seeking Alpha • 12/03/24
AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400MBusiness Wire • 12/03/24
3 Magnificent S&P 500 Dividend Stocks Down 27%, 28%, and 29% to Buy and Hold ForeverThe Motley Fool • 11/29/24